NCT01900600 - Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

January 8, 2015

Study Completion Date

January 8, 2015

Conditions

Prior Acute Myocardial InfarctionEvidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l)Reduced Left Ventricle Ejection Fraction (<50%)Symptoms of Heart Failure (NYHA Class II-III)

Interventions

OTHER

Cardiopulmonary exercise test

All patients will undergo a first CPX prior to initiation of treatment, a second one after 3 months, and a third one after 12 months of treatment.

OTHER

Echocardiogram

An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 12 months later.

Trial Locations (1)

23298

Virginia Commonwealth University, Richmond